keyword
MENU ▼
Read by QxMD icon Read
search

Marijuana and multiple sclerosis

keyword
https://www.readbyqxmd.com/read/27829351/recent-updates-in-imperative-natural-compounds-for-healthy-brain-and-nerve-function-a-systematic-review-of-implications-for-multiple-sclerosis
#1
Nima Sanadgol, Shahram Shahraki Zahedani, Mohammad Sharifzadeh, Roghayeh Khalseh, Gullam Reza Barbari, Mohammad Abdollahi
BACKGROUND: The evolution of the 'Green' movement in western society has changed attitudes in the general population who now perceive natural compounds as being inherently harmless and more desirable than artificial chemical products. OBJECTIVE: Considering the growing interest towards introducing naturally emerged medicines, the purpose of this review was to overview the ongoing research into prevention and treatment of multiple sclerosis (MS) lesions. METHOD: This review was carried out by searching bibliographic databases such as PubMed and Scopus for studies reported between 1th January 2008 to 30rd January 2016 on MS patients or animal models of MS, investigating the beneficial effects of natural compounds in MS treatment...
November 8, 2016: Current Drug Targets
https://www.readbyqxmd.com/read/27789118/adverse-structural-and-functional-effects-of-marijuana-on-the-brain-evidence-reviewed
#2
REVIEW
David E Mandelbaum, Suzanne M de la Monte
The growing use and legalization of cannabis are leading to increased exposures across all age groups, including in adolescence. The touting of its medicinal values stems from anecdotal reports related to treatment of a broad range of illnesses including epilepsy, multiple sclerosis, muscle spasms, arthritis, obesity, cancer, Alzheimer disease, Parkinson disease, post-traumatic stress, inflammatory bowel disease, and anxiety. However, it is essential that anecdotal data and the high level of interest in this treatment not obscure objective assessments of any potential and realized short- and long-term adverse effects of cannabis, particularly with respect to age of onset and chronicity of exposure...
September 13, 2016: Pediatric Neurology
https://www.readbyqxmd.com/read/27757048/medical-cannabis-the-canadian-perspective
#3
Gordon D Ko, Sara L Bober, Sean Mindra, Jason M Moreau
Cannabis has been widely used as a medicinal agent in Eastern medicine with earliest evidence in ancient Chinese practice dating back to 2700 BC. Over time, the use of medical cannabis has been increasingly adopted by Western medicine and is thus a rapidly emerging field that all pain physicians need to be aware of. Several randomized controlled trials have shown a significant and dose-dependent relationship between neuropathic pain relief and tetrahydrocannabinol - the principal psychoactive component of cannabis...
2016: Journal of Pain Research
https://www.readbyqxmd.com/read/27428345/-cannabis-effects-in-the-central-nervous-system-therapeutic-societal-and-legal-consequences
#4
Víctor Manuel Rivera-Olmos, Marisela C Parra-Bernal
The consumption of marijuana extracted from Cannabis sativa and indica plants involves an important cultural impact in Mexico. Their psychological stimulatory effect is widely recognized; their biochemical and molecular components interact with CB1 and CB2 (endocannabinoid system) receptors in various central nervous system structures (CNS) and immune cells. The psychoactive element Δ-9-tetrahydrocannabinol (THC) can be reproduced synthetically. Systematic reviews show evidence of therapeutic effectiveness of therapeutic marijuana only for certain symptoms of multiple sclerosis (spasticity, spasms and pain), despite attempts for its widespread use, including refractory childhood epilepsy...
September 2016: Revista Médica del Instituto Mexicano del Seguro Social
https://www.readbyqxmd.com/read/27086601/endocannabinoid-system-a-multi-facet-therapeutic-target
#5
REVIEW
Rimplejeet Kaur, Sneha R Ambwani, Surjit Singh
Cannabis sativa is also popularly known as marijuana. It has been cultivated and used by man for recreational and medicinal purposes since many centuries. Study of cannabinoids was at bay for very long time and its therapeutic value could not be adequately harnessed due to its legal status as proscribed drug in most of the countries. The research of drugs acting on endocannabinoid system has seen many ups and downs in the recent past. Presently, it is known that endocannabinoids has role in pathology of many disorders and they also serve "protective role" in many medical conditions...
2016: Current Clinical Pharmacology
https://www.readbyqxmd.com/read/26929665/a-urinary-test-procedure-for-identification-of-cannabidiol-in-patients-undergoing-medical-therapy-with-marijuana
#6
Paul T Wertlake, Michael D Henson
Marijuana is classified by the Drug Enforcement Agency (DEA) as Schedule I, drugs having no accepted medical value. Twenty-three states and the District of Columbia have legalized medical marijuana. This conflict inhibits physicians from prescribing marijuana and the systematic study of marijuana in medical care. This study concerns the use of the clinical laboratory as a resource for physicians recommending cannabidiol (CBD) to patients, or for patients using medical marijuana. Marijuana containing delta-9-tetrahydrocannabinol (THC) is psychoactive...
2016: Journal of Pain Research
https://www.readbyqxmd.com/read/26772776/cannabidiol-limits-tcell-mediated-chronic-autoimmune-myocarditis-implications-to-autoimmune-disorders-and-organ-transplantation
#7
Wen-Shin Lee, Katalin Erdelyi, Csaba Matyas, Partha Mukhopadhyay, Zoltan V Varga, Lucas Liaudet, György Haskó, Daniela Čiháková, Raphael Mechoulam, Pal Pacher
RATIONALE: Myocarditis is a major cause of heart failure and sudden cardiac death in young adults and adolescents. Many cases of myocarditis are associated with autoimmune processes in which cardiac myosin is a major autoantigen. Conventional immunosuppressive therapies often provide unsatisfactory results and are associated with adverse toxicities during the treatment of autoimmune myocarditis. Cannabidiol (CBD) is a non-psychoactive constituent of Marijuana which exerts antiinflammatory effects independent from classical cannabinoid receptors...
January 8, 2016: Molecular Medicine
https://www.readbyqxmd.com/read/26443472/medical-marijuana-patient-counseling-points-for-health-care-professionals-based-on-trends-in-the-medical-uses-efficacy-and-adverse-effects-of-cannabis-based-pharmaceutical-drugs
#8
Jayesh R Parmar, Benjamin D Forrest, Robert A Freeman
The purpose of this report is to present a review of the medical uses, efficacy, and adverse effects of the three approved cannabis-based medications and ingested marijuana. A literature review was conducted utilizing key search terms: dronabinol, nabilone, nabiximols, cannabis, marijuana, smoke, efficacy, toxicity, cancer, multiple sclerosis, nausea, vomiting, appetite, pain, glaucoma, and side effects. Abstracts of the included literature were reviewed, analyzed, and organized to identify the strength of evidence in medical use, efficacy, and adverse effects of the approved cannabis-based medications and medical marijuana...
July 2016: Research in Social & Administrative Pharmacy: RSAP
https://www.readbyqxmd.com/read/26336632/clinical-perspectives-on-medical-marijuana-cannabis-for-neurologic-disorders
#9
Terry D Fife, Heidi Moawad, Constantine Moschonas, Katie Shepard, Nancy Hammond
The American Academy of Neurology published an evidence-based systematic review of randomized controlled trials using marijuana (Cannabis sativa) or cannabinoids in neurologic disorders. Several cannabinoids showed effectiveness or probable effectiveness for spasticity, central pain, and painful spasms in multiple sclerosis. The review justifies insurance coverage for dronabinol and nabilone for these indications. Many insurance companies already cover these medications for other indications. It is unlikely that the review will alter coverage for herbal marijuana...
August 2015: Neurology. Clinical Practice
https://www.readbyqxmd.com/read/26103031/medical-marijuana-for-treatment-of-chronic-pain-and-other-medical-and-psychiatric-problems-a-clinical-review
#10
REVIEW
Kevin P Hill
IMPORTANCE: As of March 2015, 23 states and the District of Columbia had medical marijuana laws in place. Physicians should know both the scientific rationale and the practical implications for medical marijuana laws. OBJECTIVE: To review the pharmacology, indications, and laws related to medical marijuana use. EVIDENCE REVIEW: The medical literature on medical marijuana was reviewed from 1948 to March 2015 via MEDLINE with an emphasis on 28 randomized clinical trials of cannabinoids as pharmacotherapy for indications other than those for which there are 2 US Food and Drug Administration-approved cannabinoids (dronabinol and nabilone), which include nausea and vomiting associated with chemotherapy and appetite stimulation in wasting illnesses...
June 23, 2015: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/25649017/the-therapeutic-potential-of-cannabinoids-for-movement-disorders
#11
REVIEW
Benzi Kluger, Piera Triolo, Wallace Jones, Joseph Jankovic
There is growing interest in the therapeutic potential of marijuana (cannabis) and cannabinoid-based chemicals within the medical community and, particularly, for neurological conditions. This interest is driven both by changes in the legal status of cannabis in many areas and increasing research into the roles of endocannabinoids within the central nervous system and their potential as symptomatic and/or neuroprotective therapies. We review basic science as well as preclinical and clinical studies on the therapeutic potential of cannabinoids specifically as it relates to movement disorders...
March 2015: Movement Disorders: Official Journal of the Movement Disorder Society
https://www.readbyqxmd.com/read/25503438/medical-marijuana-for-cancer
#12
REVIEW
Joan L Kramer
Answer questions and earn CME/CNE Marijuana has been used for centuries, and interest in its medicinal properties has been increasing in recent years. Investigations into these medicinal properties has led to the development of cannabinoid pharmaceuticals such as dronabinol, nabilone, and nabiximols. Dronabinol is best studied in the treatment of nausea secondary to cancer chemotherapy and anorexia associated with weight loss in patients with acquired immune deficiency syndrome, and is approved by the US Food and Drug Administration for those indications...
March 2015: CA: a Cancer Journal for Clinicians
https://www.readbyqxmd.com/read/25427150/medical-marijuana-in-neurology
#13
REVIEW
Selim R Benbadis, Juan Sanchez-Ramos, Ali Bozorg, Melissa Giarratano, Kavita Kalidas, Lara Katzin, Derrick Robertson, Tuan Vu, Amanda Smith, Theresa Zesiewicz
Constituents of the Cannabis plant, cannabinoids, may be of therapeutic value in neurologic diseases. The most abundant cannabinoids are Δ(9)-tetrahydrocannabinol, which possesses psychoactive properties, and cannabidiol, which has no intrinsic psychoactive effects, but exhibits neuroprotective properties in preclinical studies. A small number of high-quality clinical trials support the safety and efficacy of cannabinoids for treatment of spasticity of multiple sclerosis, pain refractory to opioids, glaucoma, nausea and vomiting...
December 2014: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/25346628/cannabidiol-promise-and-pitfalls
#14
Timothy E Welty, Adrienne Luebke, Barry E Gidal
Over the past few years, increasing public and political pressure has supported legalization of medical marijuana. One of the main thrusts in this effort has related to the treatment of refractory epilepsy-especially in children with Dravet syndrome-using cannabidiol (CBD). Despite initiatives in numerous states to at least legalize possession of CBD oil for treating epilepsy, little published evidence is available to prove or disprove the efficacy and safety of CBD in patients with epilepsy. This review highlights some of the basic science theory behind the use of CBD, summarizes published data on clinical use of CBD for epilepsy, and highlights issues related to the use of currently available CBD products...
September 2014: Epilepsy Currents
https://www.readbyqxmd.com/read/25327006/-marijuana-for-medical-purposes-public-health-perspective
#15
REVIEW
Davorka Gazdek
Studies show significant negative effects of smoking marijuana on physical and mental health as well as social and occupational functioning. At the same time, there are more considerations about its ability to treat a number of diseases. This review summarizes current data in scientific literature that examines the medical effects of marijuana on human health with particular emphasis on its potential in medicine. Marijuana has a range of adverse health effects, particularly relating to young people because of higher risk for psychosis, traffic accidents, and cognitive impairment...
July 2014: Lijec̆nic̆ki Vjesnik
https://www.readbyqxmd.com/read/24971285/the-endocannabinoid-system-a-putative-role-in-neurodegenerative-diseases
#16
REVIEW
Giuseppe Di Iorio, Matteo Lupi, Fabiola Sarchione, Ilaria Matarazzo, Rita Santacroce, Filippo Petruccelli, Giovanni Martinotti, Massimo Di Giannantonio
BACKGROUND: Following the characterization of the chemical structure of D9-tetrahydrocannabinol (THC), the main psychoactive constituent of marijuana, researchers have moved on with scientific valuable explorations. OBJECTIVES: The aim of this review is to highlight the role of endocannabinoid system in neurodegenerative diseases. MATERIALS AND METHODS: The article is a critical analysis of the most recent data currently present in scientific literature on the subject; a qualitative synthesis of only the most significant articles has been performed...
December 2013: International Journal of High Risk Behaviors & Addiction
https://www.readbyqxmd.com/read/24789863/effects-of-cannabis-on-cognition-in-patients-with-ms-a-psychometric-and-mri-study
#17
Bennis Pavisian, Bradley J MacIntosh, Greg Szilagyi, Richard W Staines, Paul O'Connor, Anthony Feinstein
OBJECTIVE: To determine functional and structural neuroimaging correlates of cognitive dysfunction associated with cannabis use in multiple sclerosis (MS). METHODS: In a cross-sectional study, 20 subjects with MS who smoked cannabis and 19 noncannabis users with MS, matched on demographic and neurologic variables, underwent fMRI while completing a test of working memory, the N-Back. Resting-state fMRI and structural MRI data (lesion and normal-appearing brain tissue volumes, diffusion tensor imaging metrics) were also collected...
May 27, 2014: Neurology
https://www.readbyqxmd.com/read/24778283/systematic-review-efficacy-and-safety-of-medical-marijuana-in-selected-neurologic-disorders-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology
#18
REVIEW
Barbara S Koppel, John C M Brust, Terry Fife, Jeff Bronstein, Sarah Youssof, Gary Gronseth, David Gloss
OBJECTIVE: To determine the efficacy of medical marijuana in several neurologic conditions. METHODS: We performed a systematic review of medical marijuana (1948-November 2013) to address treatment of symptoms of multiple sclerosis (MS), epilepsy, and movement disorders. We graded the studies according to the American Academy of Neurology classification scheme for therapeutic articles. RESULTS: Thirty-four studies met inclusion criteria; 8 were rated as Class I...
April 29, 2014: Neurology
https://www.readbyqxmd.com/read/24430917/nabiximols-as-an-agonist-replacement-therapy-during-cannabis-withdrawal-a-randomized-clinical-trial
#19
RANDOMIZED CONTROLLED TRIAL
David J Allsop, Jan Copeland, Nicholas Lintzeris, Adrian J Dunlop, Mark Montebello, Craig Sadler, Gonzalo R Rivas, Rohan M Holland, Peter Muhleisen, Melissa M Norberg, Jessica Booth, Iain S McGregor
IMPORTANCE: There are no medications approved for treating cannabis dependence or withdrawal. The cannabis extract nabiximols (Sativex), developed as a multiple sclerosis treatment, offers a potential agonist medication for cannabis withdrawal. OBJECTIVE: To evaluate the safety and efficacy of nabiximols in treating cannabis withdrawal. DESIGN, SETTING, AND PARTICIPANTS: A 2-site, double-blind randomized clinical inpatient trial with a 28-day follow-up was conducted in New South Wales, Australia...
March 2014: JAMA Psychiatry
https://www.readbyqxmd.com/read/23670542/the-physical-anthropometry-lifestyle-habits-and-blood-pressure-of-people-presenting-with-a-first-clinical-demyelinating-event-compared-to-controls-the-ausimmune-study
#20
MULTICENTER STUDY
Anne-Louise Ponsonby, Robyn M Lucas, Keith Dear, Ingrid van der Mei, Bruce Taylor, Caron Chapman, Alan Coulthard, Terence Dwyer, Trevor J Kilpatrick, Anthony J McMichael, Michael P Pender, Patricia C Valery, David Williams
INTRODUCTION: Lifestyle factors prior to a first clinical demyelinating event (FCD), a disorder often preceding the development of clinically definite multiple sclerosis (MS), have not previously been examined in detail. Past tobacco smoking has been consistently associated with MS. METHODS: This was a multicentre incident case-control study. Cases (n = 282) were aged 18-59 years with an FCD and resident within one of four Australian centres (from latitudes 27°S to 43°S), from 1 November 2003 to 31 December 2006...
November 2013: Multiple Sclerosis: Clinical and Laboratory Research
keyword
keyword
57774
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"